Researchers unlock the molecular origins of Alzheimer's disease

September 6, 2017 by Leah Small
Researchers help unlock the molecular origins of Alzheimer's disease
Michael Peters, Ph.D. Credit: Virginia Commonwealth University

A "twist of fate" that is minuscule even on the molecular level may cause the development of Alzheimer's disease, VCU researchers have found.

Observations of molecules called monomers, which are present in the brain, have revealed valuable insights into the disease's pathway. Monomers resemble a chain in which each of the links is one of 20 , the building blocks of essential proteins. Problems arise when these chains repeatedly stack on top of one another to form harmful atypical amyloid , which are long, string-like structures.

Typical amyloid fibrils are made from monomer chains that contain 40 amino acid links, and may have a role in DNA transcription and other cellular processes. A comprehensive look at the brains of familial (inherited) and senile (non-inherited) Alzheimer's sufferers shows that monomers with two additional links in the amino chain—called Aβ42 monomers—lead to the devastating disease, said Michael Peters, Ph.D., professor in the Department of Chemical and Life Science Engineering in the School of Engineering.

In cases of familial Alzheimer's, mutations in the monomer production pathway leads to the higher number of monomers. It is currently unknown how they develop in brains affected by senile Alzheimer's.

Peters said it's "very bizarre" that the addition of these two naturally occurring amino acids to the end of a monomer is so consequential.

"With diseases like cancer you can have one or more mutations or sequence changes along the chain itself, which radically alters the protein's behavior," Peters said, "In the case of Alzheimer's, there are no mutations in the monomers. You are simply adding only two natural amino acids to the very end of the non-toxic monomers, which causes a catastrophe."

Researchers help unlock the molecular origins of Alzheimer's disease
Left: Normal brain tissue. Right: Plaque stains from abnormal amyloid fibrils. Credit: Virginia Commonwealth University

A twist of fate

In a healthy brain, constructed from normal monomers in a specific sequence stack neatly on top of each other, similar to floors in a building. These fibril stacks weaken as they build and can break down and "fall over."

But this isn't the case for fibrils made from Aβ42 monomers, which are much stronger. Instead of breaking, these monomers continue to stack until they form long and resilient fibrils. These fibrils are believed to cause Alzheimer's disease because they invade the membranes of neurons, which leads to cell death.

Peters and School of Engineering Ph.D. candidate Oscar Bastidas conducted computational analysis to determine why fibrils constructed of Aβ42 monomers are so resilient. They determined the two additional amino acids at the monomer end caused slight rotations of molecules in specific locations within the fibrils. This allowed the monomers to stack slightly closer together, which contributed to resiliency.

"It's a literal twist of fate," Peters said.

New drugs

Peters and Bastidas are using this research to develop drugs to disrupt the formation of fibrils constructed from Aβ42 monomers without harming the brain.

"We have to get therapeutic molecules across the rather impervious blood-brain barrier and inhibit fibril formation, while not being toxic to the body or interfering with normal bodily functions," Peters said. "This makes for a very difficult three-fold problem, but we are making progress."

Explore further: New antibodies target protein structures common to several neurological diseases

Related Stories

New antibodies target protein structures common to several neurological diseases

August 29, 2017
A new kind of antibody targets a feature shared by proteins thought to cause the most damage in Alzheimer's disease, Parkinson's disease, and related conditions, creating potential for a unified treatment approach.

Alzheimer fibrils at atomic resolution

August 4, 2016
Elongated fibres (fibrils) of the beta-amyloid protein form the typical senile plaque present in the brains of patients with Alzheimer's disease. A European research team, working in conjunction with a team from the United ...

Computer simulations explore how Alzheimer's disease starts

October 3, 2016
A new Rice University study uses computer simulations to explore the initial steps of the molecular process that leads to Alzheimer's disease.

New clues illuminate Alzheimer's roots

July 23, 2013
Scientists at Rice University and the University of Miami have figured out how synthetic molecules designed at Rice latch onto the amyloid peptide fibrils thought to be responsible for Alzheimer's disease. Their discovery ...

Alzheimer's researchers find clues to toxic forms of amyloid beta

June 10, 2016
Much of the research on Alzheimer's disease has focused on the amyloid beta protein, which clumps together into sticky fibrils that form deposits in the brains of people with the disease. In recent years, attention has turned ...

Recommended for you

Study shows video games could cut dementia risk in seniors

November 16, 2017
Could playing video games help keep the brain agile as we age?

New player in Alzheimer's disease pathogenesis identified

November 14, 2017
Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have shown that a protein called membralin is critical for keeping Alzheimer's disease pathology in check. The study, published in Nature Communications, ...

Biomarker may predict early Alzheimer's disease

November 10, 2017
Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a peptide that could lead to the early detection of Alzheimer's disease (AD). The discovery, published in Nature Communications, may ...

Smell test challenge suggests clinical benefit for some before development of Alzheimer's

November 10, 2017
Researchers at Columbia University Medical Center (CUMC) and the New York State Psychiatric Institute (NYSPI) may have discovered a way to use a patient's sense of smell to treat Alzheimer's disease before it ever develops. ...

How SORLA protects against Alzheimer's disease

November 7, 2017
Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a new protective function for a brain protein genetically linked to Alzheimer's. The findings, published in the Journal of Experimental ...

Saving neurons may offer new approach for treating Alzheimer's disease

November 6, 2017
Treatment with a neuroprotective compound that saves brain cells from dying also prevents the development of depression-like behavior and the later onset of memory and learning problems in a rat model of Alzheimer's disease. ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.